Myriad Genetics Inc specializes in genetic testing across cancer, prenatal, and mental health markets. The company’s historic revenue growth has been modest, with profitability challenges deepening over recent years, culminating in substantial operating losses in FY2025. Its strategic focus on the Cancer Care Continuum (CCC), including molecular residual disease (MRD) tests, prenatal screening expansion, and mental health testing aims to unlock new growth. However, execution risks remain high given regulatory uncertainties around FDA oversight of LDTs, reimbursement pressures, recent leadership changes, and operational cost inflation. Cash flow remains weak with negative free cash flow despite marginal positive operating cash flow in 2025. Investors should watch upcoming test volumes, reimbursement landscapes, and MRD commercialization milestones closely.